BioMarin Q2 miss pressures shares, down 3% after hours

BioMarin Pharmaceutical (NASDAQ:BMRN) Q2 results ($M): Revenues: 387.8 (+4.0%).

Key product sales: Vimizim: 122.7 (-3.8%), Kuvan: 113.3 (+3.9%), Naglazyme: 98.2 (+7.8%), Palynziq: 18.8.

Net income: (37.4) (-122.6%); non-GAAP net income: 17.1 (-14.1%); EPS: (0.21) (-133.3%).

2019 guidance: Revenues: $1,680M – 1,750M; Vimizim: $530M – 570M; Kuvan: $420M – 460M; Naglazyme: $350M – 380M; Palynziq: $70M – 100M; net income: ($85M – 45M); non-GAAP net income: $130M – 170M (all unchanged).

Shares down 3% after hours.

Previously: BioMarin Pharmaceutical EPS misses by $0.09, misses on revenue (Aug. 1)

https://seekingalpha.com/news/3485793-biomarin-q2-miss-pressures-shares-3-percent-hours